Biotech, service provider sign agreement to deliver breast cancer, Alzheimer’s tests

OSLA, Norway A Norwegian biotech has signed a service provider agreement with a Belgian company that provides gene expression-based diagnostic testing and services.

DiaGenic announced Tuesday that it had signed the agreement with DNAVision, saying it would be able to offer healthcare providers and patients in Europe with its blood-based gene-expression diagnostic test for early detection of breast cancer and Alzheimer’s disease.

“This agreement with DNAVision will provide us with the ideal launch platform across Europe for our blood-based tests for early detection of breast cancer and Alzheimer’s disease,” DiaGenic chief executive officer Erik Christensen said. “We are currently introducing the breast cancer test in India.”